3. Hemmatjo R, Motamedzade M, Aliabadi M, Kalatpour O, Farhadian M. The effect of artificial smoke compound on physiological responses, cognitive functions and work performance during firefighting activities in a smoke-diving room: an intervention study. Int J Occup Saf Ergon 2018;24:358-365.
4. Bell S, Mehta G, Moore K, Britton A. Ten-year alcohol consumption typologies and trajectories of C-reactive protein, interleukin-6 and interleukin-1 receptor antagonist over the following 12 years: a prospective cohort study. J Intern Med 2017;281:75-85.
8. KOSIS. Socio-Demographic Distribution of Alcohol Use Disorders 1-Year Prevalence. Daejeon: Ministry of Health and Welfare Korea; 2016.
9. Kim MG, Seo JI, Kim K, Ahn YS. Nationwide firefighter survey: the prevalence of lower back pain and its related psychological factors among Korean firefighters. Int J Occup Saf Ergon 2017;23:447-456.
10. Hanak C, Benoit J, Fabry L, Hein M, Verbanck P, de Witte P, et al. Changes in pro-inflammatory markers in detoxifying chronic alcohol abusers, divided by lesch typology, reflect cognitive dysfunction. Alcohol Alcohol 2017;52:529-534.
11. Kopera M, Wojnar M, Brower K, Glass J, Nowosad I, Gmaj B, et al. Cognitive functions in abstinent alcohol-dependent patients. Alcohol 2012;46:665-671.
12. Achur RN, Freeman WM, Vrana KE. Circulating cytokines as biomarkers of alcohol abuse and alcoholism. J Neuroimmune Pharmacol 2010;5:83-91.
14. He J, Crews FT. Increased MCP-1 and microglia in various regions of the human alcoholic brain. Exp Neurol 2008;210:349-358.
17. Donzis EJ, Tronson NC. Modulation of learning and memory by cytokines: signaling mechanisms and long term consequences. Neurobiol Learn Mem 2014;115:68-77.
19. King JA, Nephew BC, Choudhury A, Poirier GL, Lim A, Mandrekar P. Chronic alcohol induced liver injury correlates with memory deficits: role for neuroinflammation. Alcohol 2020;83:75-81.
20. Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol 2012;92:959-975.
22. Yen CH, Ho PS, Yeh YW, Liang CS, Kuo SC, Huang CC, et al. Differential cytokine levels between early withdrawal and remission states in patients with alcohol dependence. Psychoneuroendocrinology 2017;76:183-191.
23. Leclercq S, Cani PD, Neyrinck AM, Stärkel P, Jamar F, Mikolajczak M, et al. Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects. Brain Behav Immun 2012;26:911-918.
24. Biasucci LM. CDC/AHA Workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004;110:e560-e567.
25. Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol 2006;21:623-643.
26. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA 1984;252:1905-1907.
27. Maisto SA, Connors GJ, Allen JP. Contrasting self-report screens for alcohol problems: a review. Alcohol Clin Exp Res 1995;19:1510-1516.
28. Shields AL, Caruso JC. A reliability induction and reliability generalization study of the CAGE questionnaire. Educ Psychol Meas 2004;64:254-270.
29. Magruder-Habib K, Stevens HA, Alling WC. Relative performance of the MAST, VAST, and CAGE versus DSM-III-R criteria for alcohol dependence. J Clin Epidemiol 1993;46:435-441.
30. Park BK, Kim JS, Lee DB. Comparison of four alcoholism screening tools based on sensitivity and specificity for DSM-IV criteria. J Korean Acad Fam Med 2000;21:1427-1434.
31. Stenfors CUD, Jonsdottir IH, Hanson LL, Theorell T. Associations between systemic pro-inflammatory markers, cognitive function and cognitive complaints in a population-based sample of working adults. J Psychosom Res 2017;96:49-59.
32. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999;282:1737-1744.
33. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
34. Jose PE. ModGraph-I: A programme to compute cell means for the graphical display of moderational analyses: the internet version, Version 3.0. Victoria University of Wellington, Wellington, New Zealand 2013;Available at:
https://psychology.victoria.ac.nz/modgraph/. Accessed February 13, 2020..
35. Kraemer KL, Mayo-Smith MF, Calkins DR. Independent clinical correlates of severe alcohol withdrawal. Subst Abus 2003;24:197-209.
36. Webb GR, Redman S, Hennrikus D, Rostas JA, Sanson-Fisher RW. The prevalence and sociodemographic correlates of high-risk and problem drinking at an industrial worksite. Br J Addict 1990;85:495-507.
37. Richter K, Peter L, Rodenbeck A, Weess HG, Riedel-Heller SG, Hillemacher T. Shiftwork and alcohol consumption: a systematic review of the literature. Eur Addict Res 2021;27:9-15.
38. Noël X, Van der Linden M, d’Acremont M, Bechara A, Dan B, Hanak C, et al. Alcohol cues increase cognitive impulsivity in individuals with alcoholism. Psychopharmacology 2007;192:291-298.
39. Sharma D, Albery IP, Cook C. Selective attentional bias to alcohol related stimuli in problem drinkers and non-problem drinkers. Addiction 2001;96:285-295.
40. Lusher J, Chandler C, Ball D. Alcohol dependence and the alcohol Stroop paradigm: evidence and issues. Drug Alcohol Depend 2004;75:225-231.
41. Baune BT, Ponath G, Rothermundt M, Riess O, Funke H, Berger K. Association between genetic variants of IL-1beta, IL-6 and TNF-alpha cytokines and cognitive performance in the elderly general population of the MEMO-study. Psychoneuroendocrinology 2008;33:68-76.
42. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Int Med 2006;145:35-42.
43. Bower JK, Lazo M, Juraschek SP, Selvin E. Within-person variability in high-sensitivity C-reactive protein. Arch Int Med 2012;172:1519-1521.
44. Roberts WL. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: laboratory tests available to assess inflammation--performance and standardization: a background paper. Circulation 2004;110:e572-e576.
45. Riccio CA, Reynolds CR, Lowe P, Moore JJ. The continuous performance test: a window on the neural substrates for attention? Arch Clin Neuropsychol 2002;17:235-272.
47. Toker S, Shirom A, Shapira I, Berliner S, Melamed S. The association between burnout, depression, anxiety, and inflammation biomarkers: C-reactive protein and fibrinogen in men and women. J Occup Health Psychol 2005;10:344-362.
48. Shirom A, Melamed S. A comparison of the construct validity of two burnout measures in two groups of professionals. Int J Stress Manag 2006;13:176-200.
49. von Känel R, Bellingrath S, Kudielka B. Association between burnout and circulating levels of pro- and anti-inflammatory cytokines in schoolteachers. J Psychosom Res 2008;65:51-59.
50. Passos IC, Vasconcelos-Moreno MP, Costa LG, Kunz M, Brietzke E, Quevedo J, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry 2015;2:1002-1012.